Vai al contenuto
Antimicrobial resistance surveillance in Europe, 2020 data WHO & ECDC, January 2022Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis The Lancet, January 19, 2022, onlineAt 5 years, CARB-X celebrates progress on antibiotic development Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota2020 Antibacterial agents in clinical and preclinical development: an overview and analysis World Health Organization, 2021Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States Dzintars Gotham et al, Health Policy, November 2020 (Open Access)Precarious antibiotics supply situation: Will the Covid19 Pandemic change anything? (translation D–>E) Beyer P,, Swiss medical Forum 47-48: 701-705 (November 2020) (Open Access)Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe A look at four potential financing models with an evaluation from a European perspective Årdal C, Lacotte Y, and Ploy MC (EU-JAMRAI), Clin. Infect. Dis. 71 : 1994 (2020)No money for new drugs Despite an overwhelming global need for pharmaceutical companies to develop more antibiotics, there’s little financial incentive to encourage them Benjamin Plackett, Nature 586, 22 October 2020Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonu s Morel CM, Lindahl O. & al., J. Antibiotics 73 : 421-428 (2020)Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study Strich J.R. & al., Lancet Inf. Dis.: June 4 (2020)Antibiotic development — economic, regulatory and societal challenges Årdal C., Balasegaram M. & al., Nature Rev. Microbiol. 18 : 267 (2020)The global preclinical antibacterialpipeline Theuretzbacher U., Outterson K. & al., Nature Rev. Microbiol. 18: 275(2020)Priority pathogens and the antibiotic pipeline: an update Beyer P. & Paulin S., Bull. WHO 90 : 151 (2020)Biological Risks in Switzerland: Antibiotic resistances The Swiss Expert Committee for Biosafety SECB produced has a document for biological risks related to Antibiotic Resistance (November 2019)The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later Description of the state of antimicrobial resistance worldwide 6 years after the first report A paper from Lancet Infectious Diseases , 11 February 2020Crisis Looms in Antibiotics as Drug Makers Go Bankrupt First Big Pharma fled the field, and now start-ups are going belly up, threatening to stifle the development of new drugs A paper from the New York Times (26.12.2019)CAESAR annual report 2018 WHO Central Asian and Eastern European Surveillance of Antimicrobial Resistance report containing the Swiss data (from Anresis.ch), November 2019Swiss Antibiotic Resistance Report 2018 Anresis.ch, ARCH-Vet; November 2019Incentivising a sustainable response to the threat of AMR BEAM Alliance, November 2019Chimeric peptidomimetic antibiotics against Gram-negative bacteria Luther A., Urfer M., et al., Nature, 23 October 2019